Our Australian Natural range is grown and processed domestically, while our Global Selects range is cultivated to GACP standards by international partners and then processed in our Australian GMP facilities.
Recently, our Head of Plant Performance and Genetics, Rangi Faulder, introduced a new AN genetics library showcasing cultivars for the global market.
We consistently invest in cutting-edge research and evidence-based practices, detailed on our research page.
Find out how plant-based medicines can play a role in the holistic treatment of your patient, and the regulatory pathways required to become a prescriber.
The regulatory pathways are the Authorised Prescriber Standard Pathway and the Special Access Scheme Category B (SAS-B).
SAS-B is an application pathway that can be accessed by health practitioners. The application is approved on a case-by-case basis and requires a clinical justification for the use of the product including why plant-based medicine is preferred compared to other approved medicines and an appraisal of the expected clinical benefits verse the potential risks. An application can be submitted to the TGA via the SAS and Authorised Prescriber Online System.
An Authorised Prescriber can supply plant-based treatments directly to specified patients under their immediate care without requiring separate approval for individual patients.
The standard pathway requires a 2-step application process:
1. Submit an application to a Human Rights Ethics Committee (HREC) or a specialist college and receive approval
2. Complete an online application to the TGA using the SAS and Authorised Prescriber Online System
Key features | Authorised Prescriber | SAS-B |
---|---|---|
Medical practitioners can apply | Yes | Yes |
Other health practitioners can apply | No | Yes |
Requires submission to TGA for every patient | No | Yes |
Requires six monthly patient number reporting | Yes | No |